Literature DB >> 33182019

Treatment with 5-methoxytryptophan attenuates microglia-induced neuroinflammation in spinal cord trauma.

Xin Hong1, Fan Jiang2, You Li2, Le Fang3, Zhanyang Qian4, Hongtao Chen5, Renyi Kong6.   

Abstract

Neuroinflammation following spinal cord injury (SCI) leads to extensive secondary damage in neural tissue adjacent to the primary lesion foci. 5-Methoxytryptophan (5MTP) is a metabolite of tryptophan and proven to play a protective role in several inflammation-related diseases. However, the specific efficacy and molecular mechanism of 5MTP in SCI remains unknown. Here, we aimed to investigate the anti-inflammatory role of 5MTP in microglia-induced neuroinflammation and its therapeutic effect in SCI. To assess the effect of 5MTP in neuroinflammation, we used lipopolysaccharide (LPS) to stimulate microglia in vitro and detected the microglial phenotype using immunofluorescence staining, the inflammatory-related pathway using western blotting, and pro-inflammatory cytokines using ELISA and immunofluorescence. To explore the therapeutic effect of 5MTP in SCI, we performed contusion of the spinal cord in mice and measured the levels of neuroinflammation, glial accumulation, histological and functional recovery using ELISA, immunofluorescence staining, immunohistochemical staining, hematoxylin-eosin staining, Nissl staining and the Basso Mouse Scale, respectively. We found that treatment with 5MTP contributed to decreased activation of pro-inflammatory microglia and reduced the generation of inflammatory cytokines, including TNF-α, IL-1β, IL-6 and IL-18, by negative regulation of the p38-MAPK signaling pathway and NLRP3/caspase-1 expression. In vivo, administration of 5MTP showed mitigatory neuroinflammation levels associated with alleviated glial scar in SCI mice; hence, the neurological integrity and the neuronal survival, as well as locomotor function, were improved following 5MTP administration. 5MTP, as a novel anti-neuroinflammatory reagent, can attenuate activated microglia-induced secondary injury following SCI, and therefore, shows promise as a potential compound for application in a clinical trial for SCI therapy.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33182019     DOI: 10.1016/j.intimp.2020.106988

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  4 in total

1.  Silencing TAK1 reduces MAPKs-MMP2/9 expression to reduce inflammation-driven neurohistological disruption post spinal cord injury.

Authors:  Shuai Jiang; Yandan Wu; Shunjie Wu; Suhui Ye; Renyi Kong; Jie Chang; Mingjie Xia; Junping Bao; Xin Peng; Xin Hong; Zhanyang Qian; Haijun Li
Journal:  Cell Death Discov       Date:  2021-05-08

2.  BAY61‑3606 attenuates neuroinflammation and neurofunctional damage by inhibiting microglial Mincle/Syk signaling response after traumatic brain injury.

Authors:  Chao Gan; Huaqiu Zhang; Xuejun He; Yimin Huang; Yanchao Liu; Xincheng Zhang; Pengjie Yue; Xiaopeng Ma; Zhuangzhuang Miao; Xiaobing Long; Yiping Yang; Xueyan Wan; Jin Lei; Kai Shu; Ting Lei
Journal:  Int J Mol Med       Date:  2021-11-09       Impact factor: 4.101

3.  Ruxolitinib attenuates secondary injury after traumatic spinal cord injury.

Authors:  Zhan-Yang Qian; Ren-Yi Kong; Sheng Zhang; Bin-Yu Wang; Jie Chang; Jiang Cao; Chao-Qin Wu; Zi-Yan Huang; Ao Duan; Hai-Jun Li; Lei Yang; Xiao-Jian Cao
Journal:  Neural Regen Res       Date:  2022-09       Impact factor: 5.135

Review 4.  Beneficial Impacts of Alpha-Eleostearic Acid from Wild Bitter Melon and Curcumin on Promotion of CDGSH Iron-Sulfur Domain 2: Therapeutic Roles in CNS Injuries and Diseases.

Authors:  Woon-Man Kung; Muh-Shi Lin
Journal:  Int J Mol Sci       Date:  2021-03-24       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.